Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Leukemia

Free Subscription Articles published in Cancer Retrieve available abstracts of 103 articles: HTML format

Single Articles

April 2026
1. DANILOV AV, Coombs CC, Phillips T, Allan JN, et al
   Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
   Cancer. 2026;132:e70389.
   PubMed     Abstract available
   
   
   
2. KANTARJIAN H, Qiao W, Jain N, Jen WY, et al
   Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia.
   Cancer. 2026;132:e70401.
   PubMed     Abstract available
   
   
   
3. COSTE A, Sritharan N, Lok A, Tomowiak C, et al
   Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.
   Cancer. 2026;132:e70406.
   PubMed     Abstract available
   
   
   
4. ALONSO-DOMINGUEZ JM, Castano-Bonilla T, Gil C, Serrano-Lopez J, et al
   Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.
   Cancer. 2026;132:e70353.
   PubMed     Abstract available
   
   
   
5. LAWRENCE L
   Studies continue to individualize treatment strategies for patients with CLL and SLL: Trial data show that first-line pirtobrutinib significantly improves progression-free survival in patients with previously untreated chronic or small lymphocytic leu
   Cancer. 2026;132:e70356.
   PubMed    
   
   
   
6. LIU L, Shi Y, Wang L, Maleki Goli M, et al
   Combined prognostic impact of complex karyotype and KIT mutations refines risk stratification in t(8;21) acute myeloid leukemia.
   Cancer. 2026;132:e70370.
   PubMed     Abstract available
   
   
   
7. PERRONE S, De Fazio L, Monachetti S, Molica M, et al
   Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm.
   Cancer. 2026;132:e70372.
   PubMed     Abstract available
   
   
   
8. FRIEND R, Johnson PC, Campbell D, Rosko AE, et al
   Beyond age: Frailty-guided care in hematologic malignancies.
   Cancer. 2026;132:e70375.
   PubMed     Abstract available
   
   
   
9. KISHIMOTO K, Nakata K, Kato MS, Ikawa T, et al
   Increasing incidence and changing distribution of primary cancers in therapy-related acute myeloid leukemia: A population-based study in Osaka, Japan, 1990-2020.
   Cancer. 2026;132:e70316.
   PubMed     Abstract available
   
   
   March 2026
10. 
    Correction to "Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia".
    Cancer. 2026;132:e70347.
    PubMed    
    
    
    
11. 
    Correction to "Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia".
    Cancer. 2026;132:e70325.
    PubMed    
    
    
    
12. LAWRENCE L
    Two new options for NPM1-mutated relapsed, refractory acute myeloid leukemia: Researchers are looking into whether revumenib or ziftomenib can be combined with first-line standard-of-care treatment options.
    Cancer. 2026;132:e70275.
    PubMed    
    
    
    February 2026
13. DINARDO CD, Croden J, Abdel-Salam HM, Kadia T, et al
    Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.
    Cancer. 2026;132:e70315.
    PubMed     Abstract available
    
    
    
14. BUCHRITS S, Rozental A, Korngold N, Algor O, et al
    Glucose-6-phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2026;132:e70265.
    PubMed     Abstract available
    
    
    
15. IURLO A, Cattaneo D, Fava C, Castagnetti F, et al
    Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.
    Cancer. 2026;132:e70261.
    PubMed     Abstract available
    
    
    
16. 
    Correction to "Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: comparative analysis and usefulness of IGHV subset #2 to improve their accuracy".
    Cancer. 2026;132:e70302.
    PubMed    
    
    
    January 2026
17. 
    Correction to "Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly".
    Cancer. 2026;132:e70232.
    PubMed    
    
    
    
18. KONOPLEVA M, Pemmaraju N, Sweet KL, Stein AS, et al
    Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm.
    Cancer. 2026;132:e70243.
    PubMed     Abstract available
    
    
    December 2025
19. ARGUELLO-TOMAS M, Lynton-Pons E, Albiol N, Lopez-Ferrer A, et al
    Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia.
    Cancer. 2025;131:e70216.
    PubMed     Abstract available
    
    
    
20. SICURANZA A, Pacelli P, Santoni A, Raspadori D, et al
    Reply to "Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!".
    Cancer. 2025;131:e70214.
    PubMed    
    
    
    
21. OZDEMIR ZN, Eskazan AE
    Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!
    Cancer. 2025;131:e70215.
    PubMed    
    
    
    
22. FAN Z, Chen QW, Huang XY, Fu Q, et al
    Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.
    Cancer. 2025;131:e70225.
    PubMed     Abstract available
    
    
    November 2025
23. BAO M, Zhang XS, Li ZR, Yu L, et al
    Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia.
    Cancer. 2025;131:e70166.
    PubMed     Abstract available
    
    
    
24. QIAN CS, Wang ZH, Li Z, Yao Z, et al
    A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leuk
    Cancer. 2025;131:e70168.
    PubMed     Abstract available
    
    
    
25. OK CY, Natu A, Daneshpajouhnejad P, Fathalla LA, et al
    Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly.
    Cancer. 2025;131:e70176.
    PubMed     Abstract available
    
    
    
26. KANTARJIAN HM, Borthakur G, Daver N, DiNardo C, et al
    A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens.
    Cancer. 2025;131:e70113.
    PubMed     Abstract available
    
    
    
27. BARRIERE S, Bourgne C, Tassin T, Establie A, et al
    Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study.
    Cancer. 2025;131:e70140.
    PubMed     Abstract available
    
    
    October 2025
28. SICURANZA A, Pacelli P, Santoni A, Abruzzese E, et al
    Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study.
    Cancer. 2025;131:e70122.
    PubMed     Abstract available
    
    
    
29. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
    Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
    Cancer. 2025;131 Suppl 2.
    PubMed     Abstract available
    
    
    September 2025
30. LIAN J, Zhuang X, Chen Y, Lin Q, et al
    Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine.
    Cancer. 2025;131:e70053.
    PubMed     Abstract available
    
    
    
31. CAIROLI R, Del Castello L, Imbergamo S, Pierdomenico E, et al
    Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.
    Cancer. 2025;131:e70055.
    PubMed     Abstract available
    
    
    August 2025
32. BURTON H, Boussi L, Nemirovsky D, Derkach A, et al
    Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.
    Cancer. 2025;131:e70024.
    PubMed     Abstract available
    
    
    
33. SENAPATI J, Kantarjian HM, Kadia TM, Kekedjian J, et al
    Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia.
    Cancer. 2025;131:e70028.
    PubMed     Abstract available
    
    
    
34. WANG LL, Zhao P, Liu J, An ZY, et al
    Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.
    Cancer. 2025;131:e70044.
    PubMed     Abstract available
    
    
    
35. ARORA S, Jen WY, Yilmaz M, Deshmukh I, et al
    Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
    Cancer. 2025;131:e70032.
    PubMed     Abstract available
    
    
    
36. KAO HW, Chang H, Kuo MC, Wu JH, et al
    Genetic evolution of myeloproliferative neoplasms from chronic phase to blastic phase: An analysis of 46 paired samples.
    Cancer. 2025;131:e70048.
    PubMed     Abstract available
    
    
    
37. QIAO C, Xia Y, Guo Z, Zhu L, et al
    Splicing factor 3b subunit 1 mutation patterns and prognostic implications in myelodysplastic syndromes, acute myeloid leukemia, and chronic lymphocytic leukemia: A retrospective study of 1691 cases.
    Cancer. 2025;131:e70017.
    PubMed     Abstract available
    
    
    July 2025
38. KANTARJIAN H, Breccia M, Haddad FG, Hehlmann R, et al
    Management of chronic myeloid leukemia in 2025.
    Cancer. 2025;131:e35953.
    PubMed     Abstract available
    
    
    
39. BECKER PS
    Allogeneic transplantation provides added benefit to FMS-like tyrosine kinase 3 (FLT3) inhibitors for both low-intensity and high-intensity regimens in FLT3-mutated acute myeloid leukemia.
    Cancer. 2025;131:e35973.
    PubMed    
    
    
    
40. WU Y, Yuan X, Lai X, Liu L, et al
    KRAS mutation status critically determines the clinical outcome of patients with KMT2A-rearranged acute myeloid leukemia.
    Cancer. 2025;131:e35941.
    PubMed     Abstract available
    
    
    
41. BOYIADZIS M, Wei AH, Paiva B, Freeman SD, et al
    Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.
    Cancer. 2025;131:e35960.
    PubMed     Abstract available
    
    
    
42. PATEL SA, Khedr S, Gordon CD, Nuvvula S, et al
    Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry.
    Cancer. 2025;131:e35950.
    PubMed     Abstract available
    
    
    
43. GIAI V, Rosso T, Castagnetti F, Pregno P, et al
    Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.
    Cancer. 2025;131:e35963.
    PubMed     Abstract available
    
    
    May 2025
44. KANTARJIAN H, Jain N, Litzow MR, Luger SM, et al
    The evolving therapeutic revolution in adult acute lymphoblastic leukemia.
    Cancer. 2025;131:e35872.
    PubMed     Abstract available
    
    
    
45. ATALLAH E, Lipton JH
    Has the time for treatment-free remission in Philadelphia chromosome-positive acute lymphoblastic leukemia arrived?
    Cancer. 2025;131:e35880.
    PubMed    
    
    
    
46. WINESTONE LE, Yang J, Banerjee T, Sangaramoorthy M, et al
    Impact of neighborhood archetypes on overall mortality among young patients with acute leukemia in California.
    Cancer. 2025;131:e35863.
    PubMed     Abstract available
    
    
    April 2025
47. KANTARJIAN H, Zhai Y, Oehler VG, Jamy O, et al
    Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research.
    Cancer. 2025;131:e35832.
    PubMed     Abstract available
    
    
    
48. THAKUR RK, Wang ES
    Top advances of the year: Acute myeloid leukemia.
    Cancer. 2025;131:e35834.
    PubMed    
    
    
    
49. GOULART H, Kantarjian H, Borthakur G, Daver N, et al
    Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.
    Cancer. 2025;131:e35840.
    PubMed     Abstract available
    
    
    
50. PETERS DT, Zeidner JF
    A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents.
    Cancer. 2025;131:e35838.
    PubMed    
    
    
    
51. LEBER B, Ruiz MT, Elgendy H, Pettersson F, et al
    Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.
    Cancer. 2025;131:e35845.
    PubMed     Abstract available
    
    
    
52. KHOURI MR, Wang B, Pearson LK, Gillis-Smith AJ, et al
    Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations.
    Cancer. 2025;131:e35846.
    PubMed     Abstract available
    
    
    
53. SENAPATI J, Kadia TM, Daver NG, DiNardo CD, et al
    Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.
    Cancer. 2025;131:e35806.
    PubMed     Abstract available
    
    
    
54. PAPAYANNIDIS C, Petracci E, Zappasodi P, Fracchiolla N, et al
    INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2025;131:e35820.
    PubMed     Abstract available
    
    
    
55. NANNI J, Azzali I, Papayannidis C, Mule A, et al
    Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.
    Cancer. 2025;131:e35824.
    PubMed     Abstract available
    
    
    March 2025
56. 
    Erratum to "Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study".
    Cancer. 2025;131:e35803.
    PubMed    
    
    
    
57. BAZINET A, Bataller A, Kadia T, Daver N, et al
    A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.
    Cancer. 2025;131:e35813.
    PubMed     Abstract available
    
    
    
58. KUGLER E, Kantarjian H, Jabbour E, Khaire N, et al
    Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Cancer. 2025;131:e35773.
    PubMed     Abstract available
    
    
    
59. BROWN JC, Ma C, Shi Q, Saltz LB, et al
    The association of physical activity with survival in colon cancer versus a matched general population: Data from Cancer and Leukemia Group B 89803 and 80702 (Alliance).
    Cancer. 2025;131:e35727.
    PubMed     Abstract available
    
    
    February 2025
60. LUSKIN MR, Yin J, Lozanski G, Curran E, et al
    Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
    Cancer. 2025;131:e35750.
    PubMed     Abstract available
    
    
    
61. GYAN E, Minden MD, Kubo K, Rambaldi A, et al
    Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.
    Cancer. 2025;131:e35746.
    PubMed     Abstract available
    
    
    
62. ESKAZAN AE
    Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!
    Cancer. 2025;131:e35737.
    PubMed    
    
    
    January 2025
63. WANG L, Chen Y, Zang M, Zhou J, et al
    Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia.
    Cancer. 2025;131:e35717.
    PubMed     Abstract available
    
    
    
64. LLORET-MADRID P, Boluda B, Martinez-Lopez J, Bergua J, et al
    Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study.
    Cancer. 2025;131:e35696.
    PubMed     Abstract available
    
    
    
65. SASAKI K
    Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid).
    Cancer. 2025;131:e35704.
    PubMed    
    
    
    
66. ARGUELLO-TOMAS M, Mozas P, Albiol N, Lopez-Esteban M, et al
    Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy.
    Cancer. 2025;131:e35552.
    PubMed     Abstract available
    
    
    November 2024
67. YU L, Li W, Xu N, Liu X, et al
    Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy.
    Cancer. 2024 Nov 26. doi: 10.1002/cncr.35652.
    PubMed     Abstract available
    
    
    
68. JEN WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, et al
    Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
    Cancer. 2024 Nov 25. doi: 10.1002/cncr.35662.
    PubMed     Abstract available
    
    
    
69. ZHANG C, Gu R, Wang H, Zhou C, et al
    Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35641.
    PubMed     Abstract available
    
    
    
70. OKADA Y, Tachi N, Shimazu Y, Murata M, et al
    Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
    Cancer. 2024 Nov 4. doi: 10.1002/cncr.35627.
    PubMed     Abstract available
    
    
    
71. NIERENGARTEN MB
    Blinatumomab approved as consolidation therapy for MRD-negative B-cell precursor acute lymphoblastic leukemia.
    Cancer. 2024;130:3622.
    PubMed    
    
    
    
72. NIERENGARTEN MB
    New predictive model for treatment failure in chronic myeloid leukemia.
    Cancer. 2024;130:3621.
    PubMed    
    
    
    
73. HOANG TT, Rathod RA, Rosales O, Castellanos MI, et al
    Residential proximity to oil and gas developments and childhood cancer survival.
    Cancer. 2024;130:3724-3733.
    PubMed     Abstract available
    
    
    October 2024
74. RODRIGUEZ-ARBOLI E, Rodriguez-Veiga R, Soria-Saldise E, Bergua JM, et al
    A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35618.
    PubMed     Abstract available
    
    
    
75. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    PubMed     Abstract available
    
    
    
76. NIERENGARTEN MB
    Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
    Cancer. 2024;130:3237.
    PubMed    
    
    
    September 2024
77. LI Z, Zhang X, Zhao Y, Lu L, et al
    Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia.
    Cancer. 2024 Sep 21. doi: 10.1002/cncr.35565.
    PubMed     Abstract available
    
    
    August 2024
78. ZHANG X, Wang Y, Tian X, Sun L, et al
    Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB-positive acute lymphoblastic leukemia patients: A retrospective multicenter study.
    Cancer. 2024 Aug 13. doi: 10.1002/cncr.35481.
    PubMed     Abstract available
    
    
    
79. KANTARJIAN HM, Boissel N, Papayannidis C, Luskin MR, et al
    Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.
    Cancer. 2024 Aug 2. doi: 10.1002/cncr.35505.
    PubMed     Abstract available
    
    
    July 2024
80. JEN WY, Konopleva M, Pemmaraju N
    Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Cancer. 2024;130:2260-2271.
    PubMed     Abstract available
    
    
    June 2024
81. LABRADOR J, Martinez-Cuadron D, Boluda B, Serrano J, et al
    Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
    Cancer. 2024 Jun 19. doi: 10.1002/cncr.35431.
    PubMed     Abstract available
    
    
    May 2024
82. SENAPATI J, Kantarjian HM, Bazinet A, Reville P, et al
    Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
    Cancer. 2024 May 29. doi: 10.1002/cncr.35388.
    PubMed     Abstract available
    
    
    
83. HADDAD FG, Sasaki K, Nasr L, Short NJ, et al
    Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35384.
    PubMed     Abstract available
    
    
    
84. BAZARBACHI AH, Labopin M, Raiola AM, Blaise D, et al
    Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Tran
    Cancer. 2024 May 17. doi: 10.1002/cncr.35365.
    PubMed     Abstract available
    
    
    April 2024
85. JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
    Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
    Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
    PubMed     Abstract available
    
    
    
86. LOKE J, Labopin M, Craddock C, Socie G, et al
    Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party
    Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
    PubMed     Abstract available
    
    
    
87. WANG X, Zhang B, Zhang Q, Zhou H, et al
    Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia.
    Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316.
    PubMed     Abstract available
    
    
    March 2024
88. DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al
    Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.
    Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290.
    PubMed    
    
    
    
89. HUANG R, He H, Xu X, Lin X, et al
    Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
    PubMed     Abstract available
    
    
    
90. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    PubMed     Abstract available
    
    
    February 2024
91. DINH A, Savoy JM, Kontoyiannis DP, Takahashi K, et al
    Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35251.
    PubMed     Abstract available
    
    
    
92. GUAN F, Yang L, Chen Y, Shi J, et al
    Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232.
    PubMed     Abstract available
    
    
    January 2024
93. SEDETA E, Jemal A, Nisotel L, Sung H, et al
    Survival difference between secondary and de novo acute myeloid leukemia by age, antecedent cancer types, and chemotherapy receipt.
    Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214.
    PubMed     Abstract available
    
    
    December 2023
94. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
    Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
    Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
    PubMed     Abstract available
    
    
    November 2023
95. YANG X, Yang L, Luo A, Liu S, et al
    IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
    Cancer. 2023 Nov 29. doi: 10.1002/cncr.35129.
    PubMed     Abstract available
    
    
    
96. RUIZ J, Li Y, Cao L, Huang YV, et al
    Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35109.
    PubMed     Abstract available
    
    
    
97. NIERENGARTEN MB
    New potential therapy for relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Cancer. 2023;129:3356.
    PubMed    
    
    
    
98. GUPTA DG, Varma N, Sharma P, Truica MI, et al
    Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
    Cancer. 2023;129:3390-3404.
    PubMed     Abstract available
    
    
    October 2023
99. PULLARKAT V, Chen LS, Palmer J, Zhang J, et al
    A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35077.
    PubMed     Abstract available
    
    
    
100. GUPTA DG, Varma N, Abdulkadir SA, Sreedharanunni S, et al
     A surrogate molecular approach for the detection of Philadelphia chromosome-like B-acute lymphoblastic leukemia.
     Cancer. 2023 Oct 11. doi: 10.1002/cncr.35051.
     PubMed     Abstract available
     
     
     
101. EFFICACE F, Cottone F, Yanez B, Kota V, et al
     Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
     Cancer. 2023 Oct 6. doi: 10.1002/cncr.35021.
     PubMed     Abstract available
     
     
     September 2023
102. SASAKI K, Haddad FG, Short NJ, Jain N, et al
     Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
     Cancer. 2023 Sep 28. doi: 10.1002/cncr.35038.
     PubMed     Abstract available
     
     
     
103. GIEBEL S, Labopin M, Salmenniemi U, Socie G, et al
     Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the
     Cancer. 2023 Sep 1. doi: 10.1002/cncr.35004.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum